DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later...

Full description

Bibliographic Details
Main Authors:	Jones, R, Sheehan, B, Phillips, P, Juszczak, E, Adams, J, Baldwin, A, Ballard, C, Banerjee, S, Barber, B, Bentham, P, Brown, R, Burns, A, Dening, T, Findlay, D, Gray, R, Griffin, M, Holmes, C, Hughes, A, Jacoby, R, Johnson, T, Knapp, M, Lindesay, J, McKeith, I, McShane, R, Macharouthu, A, O'Brien, J, Onions, C, Passmore, P, Raftery, J, Ritchie, C, Howard, R
Format:	Journal article
Language:	English
Published:	BioMed Central 2009

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Similar Items